A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
A Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy of DR-105 Compared to Placebo For the Management of Menstrually-Related Migraine Headaches.
Panoramica dello studio
Stato
Condizioni
Intervento / Trattamento
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
California
-
La Mesa, California, Stati Uniti, 91942
- Teva Investigational Site
-
San Diego, California, Stati Uniti, 92108
- Duramed Investigational Site
-
San Diego, California, Stati Uniti, 92123
- Teva Investigational Site
-
San Francisco, California, Stati Uniti, 94109-4841
- Duramed Investigational Site
-
-
District of Columbia
-
Washington, District of Columbia, Stati Uniti, 20036
- Duramed Investigational Site
-
-
Florida
-
West Palm Beach, Florida, Stati Uniti, 33409
- Duramed Investigational Site
-
-
Georgia
-
Savannah, Georgia, Stati Uniti, 31406
- Teva Investigational Site
-
-
New Jersey
-
Edison, New Jersey, Stati Uniti, 08817
- Duramed Investigational Site
-
-
New York
-
New York, New York, Stati Uniti, 10022
- Duramed Investigational Site
-
-
North Carolina
-
Winston-Salem, North Carolina, Stati Uniti, 27103
- Teva Investigational Site
-
-
Oklahoma
-
Tulsa, Oklahoma, Stati Uniti, 74105
- Teva Investigational Site
-
-
Oregon
-
Medford, Oregon, Stati Uniti, 97504
- Teva Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Stati Uniti, 19114
- Duramed Investigational Site
-
Uniontown, Pennsylvania, Stati Uniti, 15401
- Teva Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Stati Uniti, 29201
- Teva Investigational Site
-
Hilton Head, South Carolina, Stati Uniti, 29926
- Teva Investigational Site
-
-
Tennessee
-
Memphis, Tennessee, Stati Uniti, 38120
- Teva Investigational Site
-
-
Texas
-
Dallas, Texas, Stati Uniti, 75234
- Duramed Investigational Site
-
Houston, Texas, Stati Uniti, 77054
- Teva Investigational Site
-
San Antonio, Texas, Stati Uniti, 78258
- Duramed Investigational Site
-
-
Virginia
-
Virginia Beach, Virginia, Stati Uniti, 23454
- Duramed Investigational Site
-
-
Washington
-
Seattle, Washington, Stati Uniti, 98105
- Duramed Investigational Site
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Premenopausal, non-pregnant, non-lactating
- History of migraine headaches without aura for at least 6 months
- History of migraine headaches associated with menstruation
- Others as directed by FDA-approved protocol
Exclusion Criteria:
- History of migraine headaches with aura or focal neurological symptoms
- Any contraindication to the use of oral contraceptives
- Others as dictated by FDA-approved protocol
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Prevenzione
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Doppio
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: 91-day Levonorgestrel Oral Contraceptive
Participants received 12 weeks (84 consecutive days) of active combination tablets containing 150 µg levonorgestrel (LNG)/30 µg ethinyl estradiol (EE), followed by 7 days of 10 µg EE monotherapy, for a total of 13 weeks.
|
Trattamento di 91 giorni composto da 84 compresse combinate blu contenenti 150 µg LNG/30 µg EE e 7 compresse gialle contenenti 10 µg EE.
Altri nomi:
|
|
Comparatore placebo: Placebo
Participants received placebo, 12 weeks (84 consecutive days) of inactive tablets, followed by an additional 7 days of inactive tablets, for a total of 13 weeks.
|
1 tablet daily to match experimental arm
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the Treatment Period
Lasso di tempo: Baseline (25-35 days before Day 1) and Days 1-91
|
The number of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) through the end of the 91-day treatment period compared with Baseline (the 25- to 35-day baseline qualification period).
Participants recorded the incidence, timing and intensity of migraines in a migraine diary during the prequalification period and throughout the 91-day treatment period.
|
Baseline (25-35 days before Day 1) and Days 1-91
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants With ≥ 50% Reduction in Migraine Frequency During the First, Second and Third Months
Lasso di tempo: Baseline, Month1, Month 2 and Month 3
|
The percentage of participants with at least 50% reduction in migraine frequency (average weekly number of migraine episodes) compared to Baseline at each month of the treatment period.
|
Baseline, Month1, Month 2 and Month 3
|
|
Change From Baseline in Average Migraine Severity
Lasso di tempo: Baseline and Month 1, Month 2 and Month 3
|
Migraine severity was recorded by participants in the Baseline qualification diary and study migraine diary during the treatment period. Participants could report a severity of none (score = 0), mild (1), moderate (2), or severe (3). In general, if a headache was mild, daily activities could be resumed and little to no medication was taken. Moderate headaches required medication and effected daily activities. Severe headaches were debilitating and required medication. Average migraine severity is defined as the sum of the severity ratings divided by the total number of migraine episodes reported during the observation period (for example, Baseline, First Month, Second Month, Third Month, and 91-Day Treatment Period). A negative change from Baseline score indicates improvement in severity. |
Baseline and Month 1, Month 2 and Month 3
|
|
Percentage of Participants Who Required Rescue Medications During the Study Period
Lasso di tempo: Baseline, Month 1, Month 2 and Month 3
|
Participants recorded use of rescue medications for migraines in the migraine diary during the course of study treatment.
|
Baseline, Month 1, Month 2 and Month 3
|
|
Change From Baseline in Migraine Disability Assessment
Lasso di tempo: Baseline and Week 15
|
The migraine disability assessment (MIDAS) test is used to determine how severely migraines affect a patient's life. Participants were asked five questions about how often their headaches limited their ability to go to work or school, to do household work or to do family or leisure activities in the past 3 months. The MIDAS score equals the sum of the days answered for each question and ranges from 0 (no disability) to approximately 270 (severe disability; the upper bound is dependent on the number of days a participant would plan to work or participate in other activities). The MIDAS score is classified into four grades of severity:
|
Baseline and Week 15
|
|
Change From Baseline in Headache Impact Test
Lasso di tempo: Baseline and Week 15
|
The Headache Impact Test (HIT) is a tool used to measure the impact headaches have on patients' ability to function on the job, at school, at home and in social situations. HIT-6 consists of 6 questions each scored on a scale from Never (6 points) to Always (13 points). The total score ranges from 36 to 78 with higher scores indicating greater impact on life. There was an error in administration of the HIT-6 in this study. Question 6 was not administered, and question 3 from the MIDAS was included instead. Therefore, the total score of the HIT-6 could not be calculated. |
Baseline and Week 15
|
|
Number of Participants With Adverse Events (AEs)
Lasso di tempo: Up to 15 weeks
|
An AE is any untoward medical occurrence in a clinical investigation participant and which does not necessarily have to have a causal relationship with this treatment or clinical study. The following definitions were used to assess AE severity: Mild: Awareness of signs or symptoms, but they are easily tolerated; Moderate: Enough discomfort to cause interference with usual activity; Severe: Incapacitating, with inability to perform usual activity. Relationship to study drug was assessed as either: None: Causal relationship can be ruled out; Possibly: Causal relationship at least reasonably possible, i.e. relationship cannot be ruled out; Definitely: Causal relationship is certain. A serious adverse event (SAE) is one that met any one of the following criteria:
|
Up to 15 weeks
|
|
Mean Number of Days of Bleeding or Spotting
Lasso di tempo: 91-day treatment period
|
Bleeding and spotting were recorded by participants in the migraine diary during the 91-day treatment period.
|
91-day treatment period
|
Collaboratori e investigatori
Sponsor
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie del cervello
- Malattie del sistema nervoso centrale
- Malattie del sistema nervoso
- Dolore
- Manifestazioni neurologiche
- Disturbi della cefalea, primaria
- Disturbi della cefalea
- Disturbi dell'emicrania
- Male alla testa
- Effetti fisiologici delle droghe
- Agenti contraccettivi, ormonali
- Agenti di controllo riproduttivo
- Agenti contraccettivi, femmina
- Contraccettivi, Orali, Sintetici
- Levonorgestrel
- Agenti contraccettivi
- Contraccettivi, orale
Altri numeri di identificazione dello studio
- DR-105-201
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .